Feasibility Trial Evaluating Efficacy and Safety of Solitaire™ Thrombus Retrieval Device in the Management of Refractory Thrombus in Patients With Acute Coronary Syndrome (Solitaire)

The study is designed as a multicentre open label prospective feasibility trial to capture preliminary efficacy and safety information on Solitaire device to plan an appropriate pivotal study.

Study Overview

• Status: Unknown
• Conditions: Refractory Thrombus in Patients With Acute Coronary Syndrome
• Intervention / Treatment: Device: Solitaire™ thrombus retrieval device

Detailed Description

We hypothesize that Solitaire device could be effectively and safely used as an adjunctive interventional technique in ACS patients found to have refractory thrombus during PCI.

1. Primary Objectives To evaluate intra-procedure efficacy of using Solitaire in ACS patients with refractory thrombus.
2. Secondary Objectives To evaluate clinical efficacy of using Solitaire in ACS patients with refractory thrombus, up to one year post-procedure.

To evaluate safety of using Solitaire in ACS patients with refractory thrombus.

The target enrolment is 51 patients diagnosed with STEMI, NSTEMI or UA and found to have refractory thrombus during PCI. Eligible patients will be identified at the ED or Inpatient ward of the 5 participating hospitals. The projected enrolment period is for two years and follow up for one year. A screening log will be maintained at each site to keep record of patients who were eligible for the study but not enrolled, to establish any selection bias.

• Study Type: Interventional
• Enrollment (Anticipated): 51
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: cathy Haiyan li, Master Degree; Phone Number: +65 63578388; Email: Haiyan_LI@ttsh.com.sg
• Study Contact Backup: Name: Iswarya Jayakumar, Degree; Phone Number: 63578326; Email: Iswarya_JAYAKUMAR@ttsh.com.sg

Study Locations

• Singapore
  • Singapore, Singapore, 768828
    • Recruiting
    • Khoo Teck Puat Hospital
    • Contact: Boon Khim Lim; Phone Number: (65)66023307; Email: lim.boon.khim@ktph.com.sg
    • Principal Investigator: Dr Syed Saqib Imran
  • Singapore, Singapore, 119074
    • Recruiting
    • National University Heart Centre Singapore (NUHCS)
    • Contact: Jolene Leong; Email: jolene_rachel_LEONG@nuhs.edu.sg
    • Principal Investigator: Dr Joshua LOH
  • Singapore, Singapore, 308433
    • Recruiting
    • Tan Tock Seng Hospital (TTSH)
    • Contact: Haiyan Li; Phone Number: (65)63578388; Email: Haiyan_LI@ttsh.com.sg
    • Principal Investigator: Dr Paul Jau Lueng Ong
  • Singapore, Singapore, 529889
    • Recruiting
    • Changi General Hospital (CGH) Changi General Hospital
    • Contact: Li Li; Phone Number: (65)68502697; Email: Li_Li@cgh.com.sg
    • Principal Investigator: Dr Yew Seong Goh
  • Singaproe
    • Singapore, Singaproe, Singapore, 169609
      • Recruiting
      • National Heart Centre Singapore (NHCS)
      • Contact: Aishah Toh; Phone Number: (65)67042282; Email: aishah.toh@nhcs.com.sg
      • Principal Investigator: Dr Aaron Sung Lung Wong

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects meeting all of the inclusion criteria listed below will be included in this study:

1. Index event of ST segment elevation or non-ST segment elevation MI or Unstable Angina defined as:

   1. Presentation to hospital with symptoms of myocardial ischemia (Chest pain or angina equivalent) lasting for ≥10 minutes at rest

      AND 1 of the following:

   2. Persistent ST segment elevation ≥1mm (0.1 mV) in two or more contiguous limb leads or ≥2mm (0.2 mV) in ) in one or more contiguous precordial leads OR
   3. New or presumed new left bundle branch block (LBBB) OR
   4. ST segment depression ≥1mm (0.1 mV) in two or more contiguous leads (not known to be pre-existing or due to a known cause such as LV hypertrophy or digoxin) OR
   5. Troponin T or I greater than the laboratory upper normal limit.

2. Referred for urgent or emergency PCI AND Thrombus burden of TG 4 or above OR TIMI flow grade of 1 or less in at least one native infarct related artery following either

   1. Manual aspiration thrombectomy OR
   2. Balloon Angioplasty OR
   3. AngioJet RT OR
   4. Patient having deferred PCI due to heavy thrombus but continue to demonstrate recalcitrant thrombus upon repeat angiography.

Exclusion Criteria:

Subjects meeting any of the exclusion criteria listed below will be excluded from this study:

1. Age ≤ 21 years
2. Cardiogenic shock
3. killip class 3 or above at presentation

4. Known relative contraindications for the use of Solitaire:

   1. Prior stent in infarct related artery
   2. Significant proximal stenosis OR Ostial lesion at angiography
   3. Extensive calcification
5. Life expectancy less than six months due to non-cardiac condition
6. Participants categorised as vulnerable subjects (ex: prisoners, pregnant women, and mentally disabled persons)
7. Patients at high risk of being lost to follow up (ex: non-residents)
8. Participation in any study with an investigational drug or device within the last 30 days
9. Patients who are unable to provide informed consent prior to any procedure .

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: open label; open label prospective feasibility trial.

Device: Solitaire™ thrombus retrieval device; After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of successful recanalization defined as an immediate post-procedure Thrombolysis in Myocardial Infarction (TIMI) flow of 2 or 3.	Primary Efficacy Endpoint	immediate post-procedure
Occurrence of any stroke	Occurrence of any stroke, defined as the presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours, from immediate post-procedure up to 30 days.	immediate post-procedure up to 30 days
Incidence of study device-related Serious Adverse Events (SAEs) up to 30 days.	Primary Safety Endpoint	up to 30 days
Incidence of emboli in new territory (ENT) at 24 hrs ± 8 hrs post procedure (ENT: Embolization territories outside of the target downstream territory).	Primary Safety Endpoint	at 24 hours ± 8 hours post procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of successful thrombus resolution defined as an immediate post-procedure thrombus burden of thrombus grade (TG) 1 or less	Secondary Endpoints	immediate post-procedure
Rate of successful recanalization defined as a reduction in corrected TIMI frame count after use of the Solitaire device.	Secondary Endpoints	immediate post-procedure
Rate of successful myocardial perfusion defined as an immediate post-procedure myocardial blush grade (MBG) of 2 or more	Secondary Endpoints	immediate post-procedure
Rate of device success defined as successful delivery and retrieval of the device without complication	Secondary Endpoints	immediate post- procedure
Occurrence of major adverse cardiac and cerebrovascular events (MACCE)	Occurrence of major adverse cardiac and cerebrovascular events (MACCE), defined as composite of all cause death, myocardial infarction, target vessel revascularisation or stroke, up to one year post-procedure.	up to one year post-procedure
All-cause mortality through 90 days post procedure.	Secondary Endpoints	90 days post procedure

Collaborators and Investigators

• Sponsor: Paul Ong
• Investigators: Principal Investigator: Paul Jau Lueng Ong, Paul Ong Jau Lueng

Study record dates

Study Major Dates

• Study Start (Actual): July 16, 2019
• Primary Completion (Anticipated): June 30, 2022
• Study Completion (Anticipated): September 30, 2022

Study Registration Dates

• First Submitted: October 28, 2020
• First Submitted That Met QC Criteria: December 29, 2020
• First Posted (Actual): December 31, 2020

Study Record Updates

• Last Update Posted (Actual): December 31, 2020
• Last Update Submitted That Met QC Criteria: December 29, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Disease; Embolism and Thrombosis; Syndrome; Thrombosis; Acute Coronary Syndrome
• Other Study ID Numbers: DSRB 2018/00865

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes